1.65

3.51% -0.06

After Hours: 1.66 0.01 +0.61%

Proqr Therapeutics N V (PRQR)

Overview News Price History Option Chain Discussions Forecast

Proqr Therapeutics N V stock is traded at $1.65, with a volume of 584.79K. It is down -3.51% in the last 24 hours and down -30.67% over the past month. ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.

Previous Close:

$1.71

Open:

$1.72

24h Volume:

584.79K

Relative Volume:

0.55

Market Cap:

$232.85M

Revenue:

$15.53M

Net Income/Loss:

$-52.71M

P/E Ratio:

-3.2836

EPS:

-0.5025

Net Cash Flow:

$-59.00M

1W Performance:

-9.84%

1M Performance:

-30.67%

6M Performance:

+4.43%

1Y Performance:

-20.29%

1-Day Range:

$1.63

$1.72

1-Week Range:

$1.63

$1.91

52-Week Range:

$1.33

$3.10

Proqr Therapeutics N V Stock (PRQR) Company Profile

Name

Proqr Therapeutics N V

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

Address

Employee

187

Twitter

@proqr

Next Earnings Date

2026-11-05

Latest SEC Filings

PRQR's Discussions on Twitter

Compare PRQR vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRQR Proqr Therapeutics N V	1.65	232.85M	15.53M	-52.71M	-59.00M	-0.5025
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-26	Resumed	Oppenheimer	Outperform
Apr-29-25	Resumed	Cantor Fitzgerald	Overweight
Apr-29-25	Initiated	Evercore ISI	Outperform
Mar-10-25	Upgrade	Citigroup	Neutral → Buy
Jan-10-25	Initiated	Oppenheimer	Outperform
Oct-29-24	Upgrade	Raymond James	Outperform → Strong Buy
Nov-08-23	Upgrade	Chardan Capital Markets	Neutral → Buy
Mar-30-23	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Dec-22-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Feb-14-22	Downgrade	Citigroup	Buy → Neutral
Feb-11-22	Downgrade	Raymond James	Strong Buy → Mkt Perform
Feb-11-22	Downgrade	Stifel	Buy → Hold
Feb-01-22	Initiated	Raymond James	Strong Buy
May-03-21	Initiated	Stifel	Buy
Mar-25-21	Reiterated	Citigroup	Buy
Nov-03-20	Resumed	Cantor Fitzgerald	Overweight
Mar-12-19	Reiterated	Chardan Capital Markets	Buy
Dec-19-18	Initiated	RBC Capital Mkts	Outperform
Nov-15-18	Initiated	Citigroup	Buy
Sep-19-18	Initiated	Evercore ISI	Outperform
Sep-26-17	Reiterated	JMP Securities	Mkt Outperform
Jun-20-16	Initiated	Chardan Capital Markets	Neutral
Oct-15-14	Initiated	Deutsche Bank	Buy
Oct-13-14	Initiated	H.C. Wainwright	Buy

View All

Proqr Therapeutics N V Stock (PRQR) Latest News

Sep 23, 2026

ProQR names AI executives as clinical data nears By Investing.com - Investing.com Canada

Sep 23, 2026

ProQR Taps AI Leaders Chris Hart and Thomas Wolf to Accelerate Axiomer RNA Editing Pipeline - tipranks.com

Sep 23, 2026

ProQR names AI executives as clinical data nears - Investing.com

Sep 23, 2026

Hugging Face co-founder joins ProQR (PRQR) to drive AI drug discovery - Stock Titan

Sep 23, 2026

Nvidia agreed to buy Hugging Face for $12.9B. Its co-founder will advise ProQR on AI. - Stock Titan

Sep 23, 2026

ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Sep 23, 2026

Sep 11, 2026

Price to sales forward of ProQR Therapeutics N.V. – SWB:0PQ - TradingView

Sep 11, 2026

Sep 10, 2026

Obesity Market to Witness Strong Growth and Significant Market Expansion by 2036 – DelveInsight | Rhythm Pharma, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical - Barchart.com

Sep 10, 2026

ProQR Therapeutics Initiates AX-0811 Clinical Trial Following First Participant Dosing - Kalkine Media

Sep 10, 2026

ProQR Therapeutics N.V.ADR Key Financial Ratios – Valuation, Profitability & More - Value Research

Sep 10, 2026

Sep 09, 2026

ProQR at Cantor conference: RNA editing pipeline gains speed By Investing.com - Investing.com Australia

Sep 09, 2026

ProQR doses first participant in AX-0811 phase 1 trial By Investing.com - Investing.com South Africa

Sep 09, 2026

ProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease Treatment - marketscreener.com

Sep 09, 2026

ProQR doses first participant in AX-0811 phase 1 trial - investing.com

Sep 09, 2026

ProQR Doses First Participant in Phase 1 Trial of AX-0811 for Cholestatic Liver Diseases - TipRanks

Sep 09, 2026

ProQR Announces First Participant Dosed in Phase 1 Study of - GlobeNewswire

Sep 09, 2026

ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving AverageShould You Sell? - marketbeat.com

Sep 09, 2026

ProQR at Cantor conference: RNA editing pipeline gains speed - Investing.com

Sep 09, 2026

symbol__ Stock Quote Price and Forecast - CNN

Sep 09, 2026

Sep 07, 2026

Enterprise value to EBIT forward of ProQR Therapeutics N.V. – NASDAQ:PRQR - TradingView

Sep 07, 2026

Sep 03, 2026

CureVac NV (CVAC) Peer Comparison – Compare with Others - Value Research

Sep 03, 2026

Sep 02, 2026

ProQR to Participate in Upcoming Investor Conferences in September 2026 - markets.businessinsider.com

Sep 02, 2026

Qiagen N.V.ADR Peer Comparison – Compare with Others - Value Research

Sep 02, 2026

Aug 29, 2026

ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Aug 29, 2026

Aug 28, 2026

ProQR Therapeutics (NASDAQ:PRQR) Share Price Crosses Above 50-Day Moving AverageWhat's Next? - MarketBeat

Aug 28, 2026

Aug 25, 2026